Surrogate and clinical endpoints in interventional cardiology: are statistics the brakes?

Conclusions: From a reimbursement impact, the primary endpoints MACE and TLR are the best choices for a moderately sized study population of 500 patients per group. Angiographic endpoints, in particular minimal lumen diameter (MLD), are not useful in this context. The emerging endpoints such as loss in FFR or stent coverage require smaller patient populations. However, their impact on reimbursement-related decisions is limited.

http://tak.sagepub.com/cgi/content/abstract/10/5/314?rss=1

Source: Therapeutic Advances in Cardiovascular Disease - August 28, 2016 Category: Cardiology Authors: Waliszewski, M., Rittger, H. Tags: Reviews Source Type: research